Summit highlights advances in avian flu vaccine research
"Since influenza is a zoonotic disease -- one that can spread among animals and humans -- it represents one of the greatest threats to human health," VaxLiant Vice President Mary Ann Pfannenstiel said. "And even when the likelihood of disease transmission from animals to humans is low, as with the H5N2 avian influenza virus currently circulating in the United States, removing animals exposed to AIV from farms can affect the available food supply. That's why discovering and developing new adjuvants to aid in prevention of disease in animals is so important to the concept of One Health."
Avian influenza vaccine research has proved innovative adjuvants can improve human health by stopping the disease from spreading. One Health Summit believes that animal health impacts human health, which is why the organization hosted a presentation about next-generation adjuvants being instrumental to containing contagious diseases.
"This research shows that using next-generation adjuvants, like ENABL, to develop new vaccines will allow us to prevent disease more effectively than ever before," Pfannenstiel said. "The technology enables a quicker vaccine-development timeline and the ability to distinguish vaccinated animals from non-vaccinates naturally exposed to a virus, both of which are important when managing outbreaks. Novel adjuvants bring these advantages and more to vaccines that will make a vital difference in both human and animal health."